PREMERA HMO

An Independent Licensee of the Blue Cross Blue Shield Association

MEDICAL POLICY – 5.01.630

Intravenous Iron Replacement Products

Effective Date:	April 1, 2024	RELATED MEDICAL POLICIES:
Last Revised:	Mar. 12, 2024	5.01.535 Erythropoiesis-Stimulating Agents
Replaces:	N/A	

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | CODING | RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | APPENDIX | HISTORY

∞ Clicking this icon returns you to the hyperlinks menu above.

Introduction

Anemia is a condition in which the number of red blood cells (RBCs) or hemoglobin (Hgb) level in them is lower than normal. Hemoglobin is a protein that carries oxygen to the body's tissues. Some symptoms of anemia include fatigue, weakness, dizziness and shortness of breath. The optimal Hgb level needed to meet an individual's needs varies by age, sex, smoking habits, and pregnancy status. Common causes of anemia include nutritional deficiencies, chronic kidney disease (CKD), irritable bowel disease, and infectious diseases. Iron is needed to make red blood cells. Intravenous iron replacement is used in severe cases to quickly replace iron stores and reduce symptoms of anemia. This policy describes when intravenous iron replacement therapy for anemia may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Intravenous Iron Replacement Products		
Preferred Agents*		
Ferrlecit (sodium ferric gluconate complex); Generic sodium ferric gluconate complex	INFeD (iron dextran)	Venofer (iron sucrose)
Non-Preferred Agents		
Feraheme (ferumoxytol); Generic ferumoxytol	Injectafer (ferric carboxymaltose)	Monoferric (ferric derisomaltose)

*Preferred agents do not need preapproval for coverage.

Drug	Medical Necessity

Feraheme (ferumoxytol) IV,
Generic ferumoxytol IV
	Feraheme (ferumoxytol) and generic ferumoxytol may be considered medically necessary for iron deficiency anemia (IDA) in adults when the following are met:
	• Individual is ≥ 18 years of age with either intolerance to oral iron or an inadequate response* to oral iron after at least 3 months of therapy
	  ○ **Exception:** No requirement for use of oral iron therapy for IDA in pregnancy or co-existing condition that would prevent absorption of oral iron therapy (e.g., gastric surgery or inflammatory bowel disease)
	OR
	• Individual is ≥ 18 years of age with chronic kidney disease
	AND
	• Individual has either intolerance to or an inadequate response* with ≥ 1 of the following preferred IV iron products:
	  ○ Ferrlecit (sodium ferric gluconate complex)
	  ○ Generic sodium ferric gluconate complex
	  ○ INFeD (iron dextran)
	  ○ Venofer (iron sucrose)
	
	Note: *See **Appendix** for lab values associated with an inadequate response to iron therapy.

Drug	Medical Necessity

Injectafer (ferric carboxymaltose) IV	**Injectafer (ferric carboxymaltose) may be considered medically necessary for the treatment of iron deficiency anemia (IDA) when all the following are met:**
	• Individual is ≥ 1 year of age with either intolerance to oral iron or an inadequate response* to oral iron after at least 3 months of therapy
	  ○ **Exception:** No requirement for use of oral iron therapy for IDA in pregnancy or co-existing condition that would prevent absorption of oral iron therapy (e.g., gastric surgery or inflammatory bowel disease)
	OR
	• Individual is ≥ 18 years of age with non-dialysis dependent chronic kidney disease
	OR
	• Individual is ≥ 18 years of age with chronic heart failure categorized as New York Heart Association (NYHA) class II or III with either intolerance to oral iron or an inadequate response* to oral iron after at least 3 months of therapy
	  ○ **Exception:** No requirement for use of oral iron therapy for IDA in pregnancy or co-existing condition that would prevent absorption of oral iron therapy (e.g., gastric surgery or inflammatory bowel disease)
	AND
	• Individual has either intolerance to or an inadequate response* with ≥ 1 of the following preferred IV iron products:
	  ○ Ferrlecit (sodium ferric gluconate complex)
	  ○ Generic sodium ferric gluconate complex
	  ○ INFeD (iron dextran)
	  ○ Venofer (iron sucrose)
	
	Note: *See **Appendix** for lab values associated with an inadequate response to iron therapy.

Monoferric (ferric derisomaltose) IV	**Monoferric (ferric derisomaltose) may be considered medically necessary for iron deficiency anemia (IDA) in adults when the following are met:**

Drug	Medical Necessity

	• Individual is ≥ 18 years of age with either intolerance to oral iron or an inadequate response* to oral iron after at least 3 months of therapy
	  ○ **Exception:** No requirement for use of oral iron therapy for IDA in pregnancy or co-existing condition that would prevent absorption of oral iron therapy (e.g., gastric surgery or inflammatory bowel disease
	OR
	• Individual is ≥ 18 years of age with non-dialysis dependent chronic kidney disease
	AND
	• Individual has either intolerance to or an inadequate response* with ≥ 1 of the following preferred IV iron products:
	  ○ Ferrlecit (sodium ferric gluconate complex)
	  ○ Generic sodium ferric gluconate complex
	  ○ INFeD (iron dextran)
	  ○ Venofer (iron sucrose)
	
	Note: *See **Appendix** for lab values associated with an inadequate response to iron therapy.

Drug	Investigational
As listed	**All other uses of the above-named drugs when used in combination with each other or for conditions not FDA approved are considered investigational.**

Length of Approval	
Approval	**Criteria**
Initial authorization	**All drugs listed in this policy may be approved up to 3 months.**
Re-authorization criteria	**Future re-authorization of all drugs listed in this policy may be approved up to 6 months in duration as long as the drug-specific coverage criteria are met and chart notes include the following:** • Documented positive response as shown by an increase in hemoglobin level of ≥1 g/dL from baseline

Length of Approval	
Approval	**Criteria**
	AND • Laboratory results demonstrating need for additional therapy

Documentation Requirements
The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following: • Office visit notes that contain the diagnosis, relevant history, physical evaluation and medication history

Coding

Code	Description
HCPC	
J1437	Injection, ferric derisomaltose (use to report Monoferric), 10 mg
J1439	Injection, ferric carboxymaltose (use to report Injectafer), 1 mg
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, (use to report ferumoxytol), 1 mg (non-ESRD use)
Q0139	Injection, ferumoxytol, for treatment of iron deficiency anemia , (use to report ferumoxytol), 1 mg (for ESRD on dialysis)

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

Consideration of Age

The ages stated in this policy for which Feraheme (ferumoxytol), generic ferumoxytol, Injectafer (ferric carboxymaltose), and Monoferric (ferric derisomaltose) are considered medically

necessary are based on the ages approved in the US Food and Drug Administration (FDA) labeling.

Benefit Application

This policy is managed through the medical benefit.

Evidence Review

Background

Summary of Evidence

Efficacy of IV Iron

For the most part, the efficacy of IV iron formulations does not seem to appreciably differ; instead, approved indications, cost, number of doses required, and safety profile are more important factors for choice of one product over another. For instance, in the dialysis setting, frequency requirement for IV iron dosing is not as important as in the non-dialysis chronic kidney disease (CKD), gastrointestinal, obstetric, or heart failure iron deficiency anemia (IDA) settings. For the latter, it is much more convenient to receive a total dosing requirement in 1-2 infusions vs 5-8.

Safety of IV Iron

Intravenous iron products have evolved from historically poorly tolerated preparations to today's safer and effective agents. Early IV iron preparations were associated with serious toxic reactions caused by labile and rapid iron release. All of today's formulations of IV iron have a carbohydrate coating surrounding an elemental iron core and stronger carbohydrate-iron complex binding, which allows a slower release of iron. The newest carbohydrate moieties (carboxymaltose, ferumoxytol, and derisomaltose) are also purported to be less immunogenic, to lower risk of hypersensitivity reactions, although infrequent.

Hypersensitivity and Anaphylaxis

With today's IV iron products, anaphylaxis is a rare albeit unpredictable event. However, all IV iron products can cause typically mild to moderate infusion reactions (eg, flushing, itching, chest tightness, arthralgias, etc.). A 2020 meta-analysis of serious/severe hypersensitivity with the newer IV iron agents that included data from 21 prospective studies (9 head-to-head) and 8,599 individuals found ferric derisomaltose (Monoferric) to have fewer serious/severe hypersensitivity reactions overall compared to ferric carboxymaltose (Injectafer) or iron sucrose (Venofer). Although, there was no significant difference in anaphylaxis between the three comparators. In a 2022 retrospective cohort study using a target trial emulation framework and data from 167,925 Medicare individuals with part D coverage between July 2013 and December 2018 found adjusted rates of anaphylaxis per 10,000 first administrations were 9.8 cases (95% CI 6.2-15.3) for iron dextran, 4.0 cases (2.5-6.6) for ferumoxytol, 1.5 cases (0.3-6.6) for ferric gluconate, 1.2 cases (0.6-2.5) for iron sucrose, and 0.8 cases (0.3-2.6) for ferric carboxymaltose. Using iron sucrose as the reference, the adjusted odds ratios (ORs) for anaphylaxis were 8.3 (95% CI 3.5-19.8) for iron dextran and 3.4 (95% CI 1.4-8.3) for ferumoxytol. One significant limitation to the generalizability of these results is that the study only included Medicare individuals. Both iron dextran (INFeD) and ferumoxytol (Feraheme) carry boxed warnings for hypersensitivity and anaphylaxis, whereas other IV iron formulations do not.

Hypophosphatemia

Hypophosphatemia is an increasingly recognized issue with IV iron administration. The mechanism is believed to involve stimulation of fibroblast growth factor 23. Head-to-head trials show ferric carboxymaltose (Injectafer) is associated with a higher rate of hypophosphatemia compared to iron dextran, ferric derisomaltose (Monoferric) or ferumoxytol (Feraheme), including severe, symptomatic, and persistent hypophosphatemia (**Table 1**).

Table 1. Hypophosphatemia Comparative Ferric Carboxymaltose Trials

NCT No.	Trial Name	Comparator	Results
NCT01307007	Hypophosphatemia With Ferric Carboxymaltose Vs. Iron Dextran in Iron Deficiency Secondary to Heavy Uterine Bleeding	Iron dextran	Serum phosphate <2.0 mg/dL: 58.8% vs 0.0%
NCT02694978	A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for	Ferumoxytol	Serum phosphate <2.0 mg/dL: 50.8% vs 0.9%

NCT No.	Trial Name	Comparator	Results
	the Treatment of Iron Deficiency Anemia (IDA)		Severe <1.3 mg/dL: 10.0% vs 0.0%
NCT03238911 NCT03237065	Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia	Ferric derisomaltose	Serum phosphate <2.0 mg/dL: 74.4% vs 8.0% Severe ≤1.0 mg/dL: 11.3% vs 0.0%
NCT02905539	A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer (HOMe_aFers_1)	Ferric derisomaltose	Serum phosphate <2.0 mg/dL: 75.0% vs 7.7%

Additionally, the results of a 2020 network meta-analysis performed to examine the comparative risk of hypophosphatemia following IV iron preparations from 8 randomized controlled trials including 5989 individuals showed ferric carboxymaltose (Injectafer) was associated with a significantly higher incidence of hypophosphatemia compared to ferric derisomaltose (Monoferric; risk ratio [RR] 7.90, 95% CI 2.10-28.0), iron sucrose (Venofer; RR 9.40, 95% CI 2.30-33.0), iron dextran (INFeD; RR 6.60, 95% CI 1.91-220.0), and ferumoxytol (Feraheme; RR 24.0, 95% CI: 2.50-220.0). No significant differences were estimated for the comparisons among ferric derisomaltose, iron sucrose, iron dextran, and ferumoxytol.

Cardiovascular Safety

No CV safety concerns have been reported in clinical trials for the newer IV iron products, ferric carboxymaltose (Injectafer), ferumoxytol (Feraheme), or ferric derisomaltose (Monoferric). Longer-term studies specifically evaluating the net clinical benefits of IV iron on CV endpoints have been limited to individuals with heart failure or end stage CKD receiving hemodialysis. No CV safety signals were observed in the hemodialysis population, and higher doses of IV iron showed a benefit on CV endpoints compared with lower dose IV iron in the heart failure population. Large CV outcome trials for IV iron are ongoing (IRONMAN, FAIR-HF, and HEART-FID).

Infection and Other Adverse Events

A meta-analysis of epidemiological studies (n=15) and RCTs (n=7) did not support a higher risk of mortality, infection, cardiovascular events, or hospitalization from IV iron in individuals with

HDD-CKD, although this conclusion is limited by small sample sizes, small event numbers, and statistical heterogeneity.

Ongoing and Unpublished Clinical Trials

Three large cardiovascular outcome trials for intravenous iron are ongoing and listed in **Table 2**.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Enrollment	Completion Date
Ongoing			
NCT02642562	Intravenous Iron Treatment in Patients with Heart Failure and Iron Deficiency	1160	Aug 2022
NCT00520780	Ferinject Assessment in Patients with Iron Deficiency and Chronic Heart Failure	456	Sept 2009
NCT03037931	Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure with Iron Deficiency	3068	June 2023
NCT03036462	Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality (FAIR-HF2)	1200	May 2024

NCT = National clinical trial, FCM = Ferric Carboxymaltose

Practice Guidelines and Position Statements

Kidney Disease Improving Global Outcomes (KDIGO) 2012

Adults with Chronic Kidney Disease (CKD) and anemia without erythropoietin stimulating agents (ESA)

IV iron (no product preference) or in NDD-CKD a 1-3 month oral iron trial if TSAT is ≤30% and ferritin is ≤500 ng/mL and not at goal.

Adults with CKD with ESA

IV iron (no product preference) or in NDD-CKD a 1-3 month oral iron trial if TSAT is ≤30% and ferritin is ≤500 ng/mL and not at goal.

Children with CKD and anemia without ESA

Oral iron (IV in HDD-CKD) if TSAT is ≤20% and ferritin is ≤100 ng/mL.

Children with CKD with ESA

Oral iron (IV in HDD-CKD) to maintain TSAT >20% and ferritin >100 ng/mL.

American Society for Clinical Oncology/American Society of Hematology (ASCO/ASH) 2019

Iron replacement may be used to improve Hgb response and reduce RBC transfusions for individuals receiving ESA therapy whether with or without iron deficiency.

2023 Update

Reviewed prescribing information for all drugs in policy and performed a literature search on the management of iron deficiency anemia. No new evidence found that would change this policy.

2024 Update

Reviewed prescribing information for all drugs in policy. Updated Injectafer (ferric carboxymaltose) to include coverage criteria for the treatment of certain adults with heart failure.

Appendix

Laboratory values associated with inadequate response to iron therapy

Iron deficiency anemia without chronic kidney disease

- Children ≥ 6 months to < 5 years:
  - Ferritin < 15 ng/mL, **and/or**
  - Hemoglobin < 11 g/dL
- Children ≥ 5 to < 12 years:
  - Ferritin < 15 ng/mL, **and/or**
  - Hemoglobin < 11.5 g/dL
- Females ≥ 12 years (Nonpregnant):
  - Ferritin < 15 ng/mL, **and/or**
  - Hemoglobin < 12 g/dL
- Females ≥ 12 years (Pregnant):
  - Ferritin < 15 ng/mL, **and/or**
  - Hemoglobin < 11 g/dL
- Males ≥ 12 to < 15 years:
  - Ferritin < 15 ng/mL, **and/or**
  - Hemoglobin < 12 g/dL
- Males ≥ 15 years:
  - Ferritin < 15 ng/mL, **and/or**
  - Hemoglobin < 13 g/dL

Iron deficiency anemia with chronic kidney disease

- Adults with CKD:
  - TSAT is ≤ 30%, **and/or**
  - Ferritin is ≤ 500 ng/mL
- Pediatric individuals < 18 years of age with CKD:
  - TSAT is < 20%, **and/or**
  - Ferritin is ≤100 ng/mL

References

1. Injectafer (ferric carboxymaltose injection) [product insert]. American Regent, Inc. Shirley, NY. Revised May 2023.
2. Feraheme (ferumoxytol injection) [product insert]. AMAG Pharmaceuticals, Inc. Waltham, MA. Revised June 2022.
3. Monoferric (ferric derisomaltose) [product insert]. Pharmacosmos Therapeutics Inc. Morristown, NJ. Revised February 2022.
4. Cohen J, Khudanyan A, Lu J, et al. A multicenter study evaluating the effectiveness and safety of single-dose low molecular weight iron dextran vs single-dose ferumoxytol for the treatment of iron deficiency. Am J Hematol. 2020;95(12):1572-1577.

5. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in hemodialyses patients treated with rHuEpo. Nephrol Dial Transplant. 2001;16(6):1239-1244.

6. Sheashaa H, El-Huseini A, Sabry A, et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharide and gluconate. Nephron Clin Pract. 2005;99(4):c97-101.

7. Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29(4):833-842.

8. Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin Am J Soc Nephrol. 2014;9(4):705-712.

9. Adkinson NF, Strauss WE, Macdougall IC, et al. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial. Am J Hematol. 2018;93(5):683-690.

10. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label comparative trial. Nephrol Dial Transplant. 2021;36(1):111-120.

11. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia: the FERWON-IDA trial. Am J Hematol. 2019;94(9):1007-1014.

12. Kahn H, May P, Kuo E, et al. Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol. Ther Adv Hematol. 2021;12:1-8.

13. Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose, and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13(2):187-195.

14. Dave CV, Brittenham GM, Carson JL, Setoguchi S. Risks of anaphylaxis with intravenous iron formulations. Ann Intern Med. 2022;175:656-664.

15. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate hemostasis in women. J Bone Min Res. 2013;28(8):1793-1803.

16. Wolf M, Rubin J, Achebe M, et al. Effects of iron maltoside vs ferric carboxymaltose on hypophosphatemia in iron deficiency anemia. JAMA. 2020;323(5):432-443.

17. Emrich IE, Lizzi F, Siegel JD, et al. Hypophosphatemia after high dosage iron substitution with ferric carboxymaltose and ferric derisomaltose --the randomized controlled HOMe aFers study. BMC Med. 2020;18(1):178.

18. Blumenstein I, Shanbhag S, Langguth P, Kalra PA, Zoller H, Lim W. Newer formulations of intravenous iron: a review of their chemistry and their key safety aspects--hypersensitivity, hypophosphatemia, and cardiovascular safety. Expert Opin Drug Safe. 2021;20(7):757-769.

19. Hougen I, Collister D, Bourrier M, et al. Safety of intravenous iron in dialysis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2018;13(3):457-467.

20. Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health-Syst Pharm. 2012;69:310-320.

21. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314(19):2062-2068.

22. Jesus-Silva JA, Lamplugh A, Dhada S, Burton JO, Bhandari S. Conversion of hemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience. BMC Nephrol. 2020;21:212.

23. World Health Organization. Health topics: anemia. Available at: **https://www.who.int/health-topics/anaemia#tab=tab_1**. Accessed March 5, 2024.

24. Batchelor EK, Kapitsinou P, Pergola PE, Kovesdy CP, Jalal DI. Iron deficiency in chronic kidney disease: updates of pathophysiology, diagnosis, and treatment. J Am Soc Nephrol. 2020;31(3):456-468.

25. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):1-335. August 2, 2012.

26. Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336-1351.

27. Choosing Wisely. American Society for Clinical Laboratory Science. Avoid using hemoglobin to evaluate patients for iron deficiency in susceptible populations. Instead, use ferritin. Released June 10, 2020. Available at: **https://www.choosingwisely.org/clinician-lists/ascls-avoid-using-hemoglobin-to-evaluate-patients-for-iron-deficiency-in-susceptible-populations-instead-use-ferritin/.** Accessed March 5, 2024.

28. WHO Guideline 1: Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations. Available at: **https://cdn.who.int/media/docs/default-source/micronutrients/ferritin-guideline/ferritin-guidelines-executivesummary.pdf?sfvrsn=8c98babb_2.** Accessed March 5, 2024.

29. Powers J, Motil K, Drutz J. et al. Iron deficiency in infants and children <12 years: Screening, prevention, clinical manifestations, and diagnosis. UpToDate. Topic last updated: Oct 20, 2021.

30. Auerbach M, Means R, Elmore J, et al. Causes and diagnosis of iron deficiency and iron deficiency anemia in adults. UpToDate. Topic last updated: Jul 07, 2022.

History

Date	Comments
12/01/22	New policy, approved November 8, 2022, effective for dates of service on or after March 1, 2023, following 90-day provider notification. Add to Prescription Drug section. Added criteria for Feraheme (ferumoxytol), generic ferumoxytol, Injectafer (ferric carboxymaltose), and Monoferric (ferric derisomaltose) for the treatment of IDA. Added HCPC codes J1437, J1439, Q0138, & Q0139.
03/01/23	Policy implementation delayed; the effective date of the policy is moved to June 1, 2023.
12/01/23	Annual Review, approved November 20, 2023. No changes to policy statements.
04/01/24	Annual Review, approved March 12, 2024. Updated Injectafer (ferric carboxymaltose) to include coverage criteria for the treatment of certain adults with heart failure.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

PREMERA HMO

Discrimination is Against the Law

Premera Blue Cross HMO (Premera HMO) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera HMO does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera HMO provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera HMO provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera HMO has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator ─ Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@Premera.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx.

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 844-722-4661 (TTY: 711).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 844-722-4661（TTY：711）。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 844-722-4661 (TTY: 711).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 844-722-4661 (TTY: 711) 번으로 전화해 주십시오.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 844-722-4661 (телетайп: 711).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 844-722-4661 (TTY: 711).

УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 844-722-4661 (телетайп: 711).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតឈ្នួល គឺអាចមានសំរាប់បំរើអ្នក។ ចូរ ទូរស័ព្ទ 844-722-4661 (TTY: 711)។

注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。844-722-4661（TTY:711）まで、お電話にてご連絡ください。

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፣ በነጻ ሊያግዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 844-722-4661 (መስማት ለተሳናቸው: 711).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 844-722-4661 (TTY: 711).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 844-722-4661 (رقم هاتف الصم والبكم: 711).

ਧਿਆਨ ਦਿਓ: ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 844-722-4661 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 844-722-4661 (TTY: 711).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັງຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 844-722-4661 (TTY: 711).

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 844-722-4661 (TTY: 711).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 844-722-4661 (ATS : 711).

UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 844-722-4661 (TTY: 711).

ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 844-722-4661 (TTY: 711).

ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 844-722-4661 (TTY: 711).

توجه: اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 844-722-4661 (TTY: 711) تماس بگیرید.